BioXcel Therapeutics appoints Dr. Rajiv Patni to Board of Directors

BioXcel Therapeutics, Inc.

Board increased from seven to eight directors on January 15, 2025.
Dr. Patni appointed as Class II director, term expiring at 2026 annual meeting.
He brings experience as CEO of Judo Bio and former CRO at Reata Pharmaceuticals.
Granted option to purchase 44,000 shares at $0.3465, vesting over three years.
Eligible for standard non-employee director compensation program.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Rajiv Patni

Director

BTAI · BioXcel Therapeutics, Inc.

Effective: 2025-01-15
Filed: January 16, 2025, 6:59 PM ET

On January 15, 2025, the Board appointed Dr. Rajiv Patni to the Board, effective January 15, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Dr. Rajiv Patni was appointed as Director at BioXcel Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On January 15, 2025, the Board appointed Dr. Rajiv Patni to the Board, effective January 15, 2025.

View on SEC.gov

BioXcel Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-003950

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.